ArticleNature2015
MAGI3-AKT3 fusion in breast cancer amended.
Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.JAMA oncology · 2021Trial
- Characteristics of fusion genes in breast cancer.Cancer cell international · 2026Review
- Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.Molecular biomedicine · 2022Review
- GeneChip expression profiling identifiedAnnals of translational medicine · 2022Article
- Review
- Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.International journal of molecular sciences · 2021Review
- AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition.Cancers · 2021Article
- Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Distinct functions of AKT isoforms in breast cancer: a comprehensive review.Cell communication and signaling : CCS · 2019Review
- Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a NovelCancer discovery · 2019Article
- MicroRNA-433 targets AKT3 and inhibits cell proliferation and viability in breast cancer.Oncology letters · 2018Article
- Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Breast cancer research and treatment · 2016Review
- Cancer: hunting rare somatic mutations.Nature methods · 2016Article
- Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers.Biomarkers in cancer · 2016Review
- Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.NPJ breast cancer · 2016Review
- Pugh et al. reply.Nature · 2015Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.